Volition Expands Fujifilm Deal to Cover Feline Cancer Blood Test
VolitionRx extends its Fujifilm contract to include a cat-focused liquid biopsy test, targeting Japan's nearly nine million cats.
VolitionRx Limited has broadened its existing contract with Fujifilm to encompass the Nu.Q Vet Feline Test, a blood-based cancer screening tool designed specifically for cats, the Nevada-based company announced Monday from Henderson.
The expansion opens the door to Japan's feline population of nearly nine million animals, representing a substantial commercial opportunity for the diagnostic technology. Volition says the test is designed to be simple and affordable, two attributes the company believes are critical to widespread veterinary adoption.
Read more Xtant Medical Posts Q3 2026 Results, Launches Strategic Review →
If cleared for market, the Nu.Q Vet Feline Test would become what Volition describes as the world's first liquid biopsy blood test built exclusively for cancer detection in cats. Liquid biopsy technology works by identifying biological markers in a blood sample rather than requiring invasive tissue procedures, a significant advantage in veterinary settings where minimizing patient stress is a clinical priority.
The move follows Volition's earlier contract with Fujifilm covering canine applications of the Nu.Q Vet platform, suggesting a deliberate strategy to broaden the technology's reach across companion animal species. Analysts tracking the veterinary diagnostics sector have noted growing demand for non-invasive cancer screening tools as pet ownership and spending on animal healthcare rise across developed markets, particularly in Asia.
Volition has not disclosed financial terms of the expanded agreement. Continue reading at All Financial Services & Investing.